Get Involved
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Study Purpose
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Observational |
| Eligible Ages | 18 Years and Over |
| Gender | All |
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT04056247 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
|
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
OncoHost Ltd. |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Alona Zer, MDMichal Lotem, MDJair Bar, MDMaya Gottfried, MDAbed Agbaria, MDIdo Wolf, MDMahmud Abu-Amana, MDRivka Katsenelson, MDAlexander Yakobson, MDTatiana Harkovsky, MDMor Moskovitz, MDElizabeta Dudnik, MDRaya Leibowitz, MDAdam Berger, MDJose Lutzky, MDAntony Magliocco, MDGillian Price, MDHelen CheleyLouise Medley, MDTom Geldart, MDAnirban Chatterjee, MDSean Brown, MDAndreas Polychronis, MDAndreas Polychronis, MDAri VanderWalde, MDDavika Das, MDAlison Brewster, MDAdam HassaniAdam Hassani, MDAndrew Conn, MDYanyan Lou, MDIgor Puzanov, MDErnesto Bustinza, MDHuang Quillan, MDRonnie Shapira Frommer, MDAstrid Ammendola, MDPetros Christopoulos, MDMarina Messinger, MDSunil Patel, MDBharat P Jenigiri, MDDavid Vecente, MDEugenie Younger, MD |
| Principal Investigator Affiliation | Rambam Health Care CampusHadassah Medical OrganizationSheba Medical CenterMeir Medical CenterBnai Zion Medical CenterTel-Aviv Sourasky Medical Centerhaemek medical centerKaplan Medical CenterSoroka University Medical CenterBarzilai Medical CenterRabin Medical CenterAssuta Medical CenterAssaf-Harofeh Medical CenterRutgers Cancer InstituteUniversity of MiamiProtean BioDiagnosticsAberdeen Royal InfirmarySwansea Bay UHB - Cancer InstituteTorbay and South Devon NHS foundationRoyal Bournemouth General Hospital DorsetThe Shrewsbury and Telford HospitalGloucestershire Hospitals NHS Foundation TrustMount Vernon Cancer CentreLister HospitalWest ClinicVAHCS BirminghamWithybush Hospital Hawl Dda University Health BoardSunderland Royal HospitalSouth Tyneside DistrictBradford Teaching HospitalsMayo ClinicRoswell ParkFlorida Cancer Specialists and Research InstituteMichael E. DeBakey VA Medical CenterSheba Medical CenterAsklepios Klinik Gauting GmbHThoraxklinik-Heidelberg gGmbHNorthwest Community HealthcareCHRISTUS St. Michael Health SystemPhysicians Clinic of IowaHospital Universitario Virgen MacarenaGloucestershire Hospitals NHS Foundation Trust |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
| Overall Status | Active, not recruiting |
| Countries | Germany, Israel, Spain, United Kingdom, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer, Stage IIIb-d Malignant Melanoma |
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
